AGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
AGENUS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$6.18+0.14 (+2.32%)
Close on Oct 19, 2026
- Market cap
- $255.47M
- P/E (TTM)
- –
- Dividend yield
- –
Agenus statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Agenus | Industry median |
|---|---|---|
| Market Cap | $278.23M | $197.05M |
| Enterprise Value | $282.78M | $106.56M |
| PS Ratio | 2.10 | 3.93 |
Enterprise value
| Measure | Agenus | Industry median |
|---|---|---|
| EV / Sales | 2.13 | 2.69 |
| EV / EBITDA | 6.91 | 14.86 |
| EV / EBIT | 7.81 | 19.00 |
Income (trailing twelve months)
| Measure | Agenus | Industry median |
|---|---|---|
| Revenue | $132.69M | $57.94M |
| Gross Profit | $132.05M | $90.47M |
| Operating Income | $36.20M | -$21.44M |
| EBITDA | $40.93M | -$16.91M |
Margins
| Measure | Agenus | Industry median |
|---|---|---|
| Gross Margin | 99.5% | 52.3% |
| Operating Margin | 27.3% | -44.5% |
| EBITDA Margin | 30.8% | -31.3% |
| FCF Margin | -74.2% | -8.85% |
Growth
| Measure | Agenus | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 30.5% | 6.01% |
| Revenue Growth (3Y CAGR) | 5.22% | 2.25% |
| Revenue Growth (5Y CAGR) | 5.31% | 6.42% |
Balance sheet
| Measure | Agenus | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $18.74M | $62.42M |
| Total Debt | $30.07M | $120.13M |
| Net Cash (Debt) | -$11.33M | $15.68M |
| Net Cash Per Share | -$0.25 | $0.65 |
| Equity (Book Value) | -$199.08M | $48.79M |
| Book Value Per Share | -$4.42 | $1.36 |
| Tangible Book Value | -$226.05M | $23.06M |
| Working Capital | -$153.01M | $75.77M |
Financial position
| Measure | Agenus | Industry median |
|---|---|---|
| Current Ratio | 0.34 | 3.30 |
| Quick Ratio | 0.14 | 2.39 |
| Debt / EBITDA | 0.73 | 3.35 |
| Net Debt / EBITDA | 0.28 | 2.22 |
| Interest Coverage | 0.61 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Agenus | Industry median |
|---|---|---|
| Operating Cash Flow | -$98.50M | -$12.35M |
| Capital Expenditures | $0 | -$1.06M |
| Free Cash Flow | -$98.50M | -$20.28M |
| FCF Per Share | -$2.19 | -$0.41 |
Efficiency
| Measure | Agenus | Industry median |
|---|---|---|
| Asset Turnover | 0.74 | 0.38 |
| Revenue Per Employee | $1.64M | $398.96K |
| Employee Count | 81 | 73 |
Dividends and yields
| Measure | Agenus | Industry median |
|---|---|---|
| FCF Yield | -35.4% | -7.64% |
Shares
| Measure | Agenus | Industry median |
|---|---|---|
| Shares Outstanding | 45,020,400 | 59,128,900 |
| Shares Change (YoY) | 51.1% | 11.1% |
| Shares Change (QoQ) | 10.6% | 0.54% |
| Float | 42,056,000 | 48,744,500 |
| Shares Held by Insiders | 6.58% | 11.8% |
| Shares Held by Institutions | 31.7% | 59.4% |
Scores
| Measure | Agenus | Industry median |
|---|---|---|
| Altman Z-Score | -16.54 | 0.10 |
Calculated by StockData from Agenus's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.